The Egyptian Drug Authority (EDA) hosted an academic delegation from Peking University, China, in cooperation with Galala University, where a roundtable and panel discussion were held under the chairmanship of Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority, as part of ongoing efforts to strengthen international cooperation in the pharmaceutical sector.
The event was attended by a number of faculty members and researchers from Galala University, including: Prof. Amira Abdel Moteaal, Dean of the Faculty of Pharmacy; Prof. Dina Farouk Sayed, Professor of Pharmacology and Toxicology; Assoc. Prof. Mohamed Salah Ahmed Toaima, Assistant Professor of Pharmaceutics and Industrial Pharmacy; and Assoc. Prof. Mariam Hassan Abdelmonem, Assistant Professor of Microbiology and Immunology.
The Chinese delegation from Peking University included Prof. Ming Xu, Dean of the Department of Global Health and Vice Dean of the Institute for Global Health and Development; Qi Wei He, Assistant Researcher at the Chinese Academy of International Trade and Economic Cooperation (CAITEC); and Xiaoyi Yu, PhD candidate in Global Health at the School of Public Health, Peking University.
During the meeting, Dr. Tamer Elhossieny emphasized the EDA’s commitment to localizing pharmaceutical manufacturing as a national strategic priority, in line with Egypt’s direction toward strengthening drug security and achieving sustainability in the healthcare sector. He highlighted the Authority’s continued efforts to offer investment incentives, foster a supportive regulatory environment, and adopt an open-door policy to enhance international partnerships.
The event also featured extensive discussions on advancing the pharmaceutical sector and expanding prospects for joint cooperation through the exchange of expertise and perspectives in regulatory and scientific fields between the Egyptian and Chinese sides.
EDA delivered a detailed presentation on the registration procedures for both conventional and innovative pharmaceutical products, outlining approved pathways and evaluation mechanisms to ensure rapid access to medicines while maintaining the highest standards of quality, safety, and efficacy.
Additionally, an overview was provided on the registration of biological products, including regulatory pathways for accelerated registration and evaluation requirements, as part of the Authority’s efforts to streamline procedures and enhance regulatory efficiency.
EDA also reviewed its key achievements in developing regulatory frameworks, highlighting its attainment of Maturity Level 3, reflecting its commitment to implementing international best practices in pharmaceutical regulation and improving the efficiency and effectiveness of regulatory processes.
Furthermore, the Authority presented its efforts to support the localization of the pharmaceutical industry through a dedicated committee responsible for developing policies and mechanisms to boost local production and attract high-quality investments, contributing to self-sufficiency and enhancing the sector’s competitiveness.
For their part, the delegations from Peking University and Galala University commended the tangible progress made by the Egyptian Drug Authority in advancing its regulatory system and improving procedural efficiency. They expressed appreciation for the Authority’s ongoing efforts to support pharmaceutical localization and provide an investment-friendly regulatory environment, reflecting its commitment to international standards and elevating the pharmaceutical sector at both regional and global levels.
Discussions also addressed technical and regulatory aspects of pharmaceutical product registration, including conventional, innovative, and biological products, within the framework of EDA’s commitment to simplifying procedures and accelerating access to medicines while ensuring the highest levels of quality, safety, and efficacy.
Both sides further emphasized the importance of strengthening regional manufacturing capacities, particularly in Africa and the Middle East, in light of global challenges that have highlighted the risks of reliance on a limited number of manufacturing hubs. They stressed the importance of technology transfer, supporting scientific research, and expanding joint manufacturing initiatives to achieve sustainable development in the pharmaceutical sector.
This comes as part of the Egyptian Drug Authority’s commitment to strengthening international cooperation frameworks and exchanging expertise with global academic and research institutions, thereby supporting the development of the pharmaceutical sector, enhancing its production and research capabilities, and opening broader horizons for international partnerships—ultimately contributing to drug security and sustainability in the healthcare sector.